John Hamill - SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
SrVP/CFO/Prin Fin & Acct Ofcr
Stock Symbol
APRE on Nasdaq
Industry
Pharmaceutical Preparations
All Insider Reports
All Insider Reports

John Hamill - trading volume in the past year for Aprea Therapeutics, Inc.

Holdings reported by John Hamill for Aprea Therapeutics, Inc.

Class Num Shares Value Price $ Report Date Ownership Underlying Class Underlying Amount
Common Stock 18,868 $138 K $7.29 Mar 28, 2024 Direct
Stock Options (Right to Buy) 13,460 Mar 28, 2024 Direct Common Stock
Tranche A Warrant 505 Mar 13, 2024 Direct Common Stock
Tranche B Warrant 505 Mar 13, 2024 Direct Common Stock

Transactions reported by John Hamill for Aprea Therapeutics, Inc.

Sym Class Transaction % Value $ Price $ Shares Shares After Date Ownership